Abstract
Since the market withdrawal of the ASR hip resurfacing in August 2010 because of a higher than expected revision rate as reported in the Australian Joint Replacement Registry (AOAJRR), metal-on-metal hip resurfacing arthroplasty (MoMHRA) has become a controversial procedure for hip replacement. Failures related to destructive adverse local tissue reactions (ALTR) to metal wear debris have further discredited MoMHRA. Longer term series from experienced resurfacing specialists, however, demonstrate good outcomes with excellent 10- to 15-year survivorship in young and active men. Besides, all hip replacement registries report significantly worse survivorship of total hip arthroplasty (THA) in patients under 50 compared to older ages. The triad of a well-designed device, implanted accurately, in the correct patient has never been more critical than with MoMHRA implants.
The surgical objectives of MoMHRA were to preserve bone stock, maintain normal anatomy and mechanics of the hip joint and to approximate the normal stress transmission to the supporting femoral bone. The functional objectives were better sports participation, less thigh pain and limp, less perception of a leg length difference and a greater perception of a normal hip. Cobb reported that patients with MoMHRA were able to walk faster and with more normal stride length than patients with well performing hip replacements. They also show that function following hip replacement is very good, with high satisfaction rates, but the use of a patient centered outcome measure (PCOM), and objective measures of function reveal substantial inferiority of THA over MoMHRA in two well-matched groups. When coupled with the very strong data regarding life expectancy and infection, this functional data makes a compelling case for the use of resurfacing in active adults.
Recent studies show a possible increase in life expectancy with MoMHRA. Compared with uncemented and cemented total hip replacements, Birmingham hip resurfacing has a significantly lower risk of death in men of all ages. McMinn's investigations additionally suggest a potentially higher mortality rate with cemented total hip replacements. These results have now been confirmed by other centers as well, and confirm that those undergoing MoMHRA have reduced mortality in the long term (up to 10 years) compared with those undergoing THA and that this difference persisted after extensive adjustment for confounding factors.
Early revisions were often due to fracture of the femoral neck while later revisions are associated with loosening and/or ALTR to wear debris. In some studies, revisions of MoMHRA with ALTR have been complicated by an increased risk of re-revision and poor outcome. Component malpositioning is the most common cause of MoMHRA failure. Metal ion measurements are an excellent tool to detect wear at an early stage. The revision analysis highlights the importance of surgical experience, indications and prosthesis design. Use of ion levels, big THA-heads and patient education/compliance were identified as factors improving outcome following MoMHRA revision.
Today's MoMHRA is conservative to the bone. It is the first implant that proves decrease of wear in time, disappearance of wear in longer term with a possible life time survival of the implant, this unrelated to the activity of the patient. If following an international consensus, the right implant is used, with a perfect technique in the right patient, all benefits exceed the problems described in the past.
